Information Provided By:
Fly News Breaks for September 27, 2019
HOOK
Sep 27, 2019 | 07:04 EDT
H.C. Wainwright analyst Debjit Chattopadhyay started Hookipa Pharma with a Buy rating and $15 price target. With clinical validation for both VaxWave and TheraT anticipated prior to the end of 2020, Hookipa "could have a lot to talk about over the next 12 to 16 months," Chattopadhyay tells investors in a research note.
News For HOOK From the Last 2 Days
There are no results for your query HOOK